Reshaping the HIV treatment and prevention landscape
RSV Maternal
Potential to provide broad protection to infants from first breath of life
One of the largest unmetneed in pediatrics
3.2m
hospitalisations
globally in
under 5s
No. 1
cause of
hospitalisation
in under 5s
1.4m
hospitalisations
in infants aged
under 6 months
More hospitalisations in first 2 years of life
Maternal Vx
40
30
20
US infant hospitalisation (in thousands)
Paediatric Vx
Polyclonal protection with potential game-
changing RSV pertussis combo to follow
- Differentiated approach with polyclonal passive
immunity designed to offer broad protection
across strains
- Positive Phase 2 data through maternal
antibody transfer to baby, launch 2024*
Potential protection of the mother & reduced
transmission risk from mother to child
Developing next generation RSV and
pertussis combination; FTIH 2022
gsk
10
0
0-3 mths 4-6 mths 7-12 mths
1-2 yrs
3-4 yrs
>4 years
Source: Adapted from Paramore LC et al. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004.
*subject to regulatory approval
67View entire presentation